AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca recently completed a clinical study titled Randomized, DB, Crossover Study to Assess Bronchospasm Potentially Induced by HFO MDI vs. HFA MDI Propellant in Participants With Asthma Well/Partially Controlled on SABA With or Without Low-Dose ICS. The study aimed to evaluate the safety and tolerability of HFO MDI compared to HFA MDI in asthma patients, focusing on changes in lung function and bronchospasm events.
The study tested two interventions: HFO MDI and HFA MDI, both administered as four inhalations per dose. HFO MDI is the experimental treatment, while HFA MDI serves as the reference.
This phase 3b trial was interventional, randomized, and double-blind, with a crossover design. The primary purpose was treatment-focused, ensuring participants, care providers, and investigators remained unaware of the treatment allocations.
The study began on May 2, 2023, with results first submitted on August 19, 2024. The last update was submitted on July 29, 2025. These dates mark the progression and completion of the study, providing a timeline for data analysis and reporting.
The completion of this study could impact AstraZeneca’s stock performance positively, as it may lead to the introduction of a new asthma treatment option, enhancing their competitive position in the respiratory market. Investors should monitor further updates and results to gauge the full market impact.
The study is completed, and further details are available on the ClinicalTrials portal.